☰

Samar A. Hegazy, Ph.D. - Publications

Affiliations: 
2012 Laboratory Medicine and Pathology University of Alberta, Edmonton, Alberta, Canada 
Area:
Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Hegazy SA, Alshareef A, Gelebart P, Anand M, Armanious H, Ingham RJ, Lai R. Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. Cellular Signalling. 25: 295-307. PMID 23022960 DOI: 10.1016/J.Cellsig.2012.09.027  0.622
2013 Hegazy SA, Alshareef A, Gelebart P, Anand M, Armanious H, Ingham RJ, Lai R. Corrigendum to "Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma" [Cell. Signal. 2013; 25:295-307] Cellular Signalling. 25: 580. DOI: 10.1016/J.Cellsig.2012.11.013  0.592
2012 Mereniuk TR, Maranchuk RA, Schindler A, Penner-Chea J, Freschauf GK, Hegazy S, Lai R, Foley E, Weinfeld M. Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1-depleted cancers. Cancer Research. 72: 5934-44. PMID 22962271 DOI: 10.1158/0008-5472.Can-12-0939  0.556
2012 Gelebart P, Hegazy SA, Wang P, Bone KM, Anand M, Sharon D, Hitt M, Pearson JD, Ingham RJ, Ma Y, Lai R. Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma. Blood Cancer Journal. 2: e82. PMID 22885405 DOI: 10.1038/Bcj.2012.27  0.618
2012 Wang P, Zhang JD, Wu F, Ye X, Sharon D, Hitt M, McMullen TP, Hegazy SA, Gelebart P, Yang J, Ma Y, Lai R. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma. Cellular Signalling. 24: 1955-63. PMID 22743134 DOI: 10.1016/J.Cellsig.2012.06.005  0.629
2011 Young LC, Bone KM, Wang P, Wu F, Adam BA, Hegazy S, Gelebart P, Holovati J, Li L, Andrew SE, Lai R. Fusion tyrosine kinase NPM-ALK deregulates MSH2 and suppresses DNA mismatch repair function: Novel insights into a potent oncoprotein American Journal of Pathology. 179: 411-421. PMID 21703420 DOI: 10.1016/J.Ajpath.2011.03.045  0.596
2010 Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions Journal of Biological Chemistry. 285: 19813-19820. PMID 20424160 DOI: 10.1074/Jbc.M110.121988  0.544
2009 Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM, Lai R. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. The American Journal of Pathology. 175: 825-34. PMID 19608866 DOI: 10.2353/Ajpath.2009.080982  0.518
Show low-probability matches.